[ad_1]
The companies said they submitted this request on Monday, completing the review process initiated by BioNTech and Pfizer after submitting the source material on October 6.
Rival Moderna also said it had applied for approval of its COVID-19 vaccine against coronavirus infection in the United States and Europe, with official studies showing 94.1 percent effectiveness.
The BioNTech report says that if the vaccine under the working name BNT162b2 is approved, vaccinations in Europe could start before the end of this year.
On November 20, Pfizer and BioNTech applied for permission from the US Food and Drug Administration (FDA) to use the vaccine in an emergency (US).
If the FDA turns the green light on, vaccines for Americans could begin in mid-December.
The UK supervisory authority is also inspecting BioNTech and Pfizer.
“We knew from the beginning of this journey that patients were waiting and we were ready to ship COVID-19 as soon as potential permits allowed,” said Albert Bourla, CEO of Pfizer.
The Moderna, Pfizer and BioNTech vaccines are based on new technology that uses information from ribonunucleic acid (mRNA) to deliver genetic material that causes human cells to produce a viral protein. The immune system, in response to this disease-free protein, remembers this antigen and is ready to attack faster if faced with a new coronavirus.
The Moderna vaccine can be stored at -20 degrees Celsius for a long time, and the Pfizer vaccine requires -70 degrees Celsius.
Both vaccines have been developed at an impressive rate, with unprecedented efforts to end the pandemic. The new coronavirus has already infected more than 62 million people around the world. people, more than 1.4 million. of them died.
Pfizer and BioNTech previously said they expect to produce up to $ 50 million this year. its vaccine doses worldwide and up to 1.3 billion by the end of 2021. doses.
[ad_2]
